Abstract Number: 0380 • ACR Convergence 2024
Joint Acoustic Emissions as a Digital Biomarker for Knee Inflammation in Juvenile Idiopathic Arthritis: A Pilot Study Using Musculoskeletal Ultrasound as Ground Truth
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic childhood arthropathy affecting 1 in 1000 children under 16, classified into seven categories by ILAR. Commonly, JIA…Abstract Number: 0404 • ACR Convergence 2024
Methotrexate Adherence in JIA: Use of Electronic Health Record-Linked Pharmacy DispensingData
Background/Purpose: The extent to which adherence to prescribed treatment regimens contributes to differential disease outcomes in JIA – and demographic disparities in these outcomes –…Abstract Number: 1028 • ACR Convergence 2024
Assessment of Patient-Reported Outcomes in Juvenile Idiopathic Arthritis by Race, Ethnicity, and Insurance Type in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry
Background/Purpose: As healthcare moves towards more patient-centered care, it is increasingly important to integrate patients’ opinions into clinical assessments and decision-making. The Pediatric Rheumatology Care…Abstract Number: 1269 • ACR Convergence 2024
Altered Tryptophan Metabolism in Juvenile Dermatomyositis Is Associated with Muscle Damage and Mental Health
Background/Purpose: Children with juvenile dermatomyositis (JDM) and juvenile idiopathic arthritis (JIA) experience impaired quality of life and high rates of anxiety and depression. The underlying…Abstract Number: 1305 • ACR Convergence 2024
Bingo: A Winning Pediatric Rheumatology Teaching Strategy?
Background/Purpose: Exposure to pediatric rheumatology is often lacking during training given that 33% of medical schools and 36% of residency programs have no affiliated pediatric…Abstract Number: 1777 • ACR Convergence 2024
Broad Proteomic Analysis Reveals Top Differential Protein Modules and Functional Annotations with Clinical Traits in Juvenile Dermatomyositis (JDM) and Myositis-Specific Autoantibody (MSA) Groups
Background/Purpose: JDM is a heterogenous systemic autoimmune disease with muscle and skin pathology, which can be clinically subgrouped by MSAs (ex: anti-TIF1, anti-MDA5 autoantibodies (Ab)).…Abstract Number: 2043 • ACR Convergence 2024
Evaluation of Medication Adherence of FMF Patients Transitioned from a Pediatric Clinic to an Adult Clinic: A Cross-sectional Study
Background/Purpose: Familial Mediterranean Fever (FMF) typically begins in childhood. It has been demonstrated that colchicine can reduce FMF attacks, prevent the development of amyloidosis, and…Abstract Number: 2193 • ACR Convergence 2024
Prospective Evaluation of Reactogenicity and Safety Following COVID-19 Vaccination in Children with a History of MIS-C
Background/Purpose: A rare subset of children who contract SARS-CoV-2 later develop the hyperinflammatory condition known as multisystem inflammatory syndrome in children (MIS-C). There has been…Abstract Number: 2500 • ACR Convergence 2024
Description of Patients with Refractory Kawasaki Disease at a Large Tertiary Center
Background/Purpose: Kawasaki disease (KD) is the leading cause of acquired heart disease in developed countries due to the development of coronary artery aneurysms (CAAs). Intravenous…Abstract Number: 2628 • ACR Convergence 2024
Clinical Features, Treatments, and Outcomes of a Large International Cohort of Childhood-onset Takayasu Arteritis: A PedVas Study
Background/Purpose: Takayasu arteritis (TAK) is a rare systemic vasculitis. It occurs most commonly in patients aged < 40 years (y), and 32% of patients present…Abstract Number: 0382 • ACR Convergence 2024
Comparative Analysis of Tear-based S100 Proteins, Cytokines, and Chemokines Levels in Juvenile Idiopathic Arthritis Associated-uveitis: Insights into Eye Laterality and Severity of Ocular Inflammation
Background/Purpose: Juvenile idiopathic arthritis-associated uveitis (JIA-U) is an ocular disease that can be unilateral or bilateral. Measurement of ocular inflammation is performed by ophthalmic examination…Abstract Number: 0405 • ACR Convergence 2024
Olokizumab, a Monoclonal Antibody Against IL-6, in Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA): Results of 24 Weeks of the Phase 2 Open-label Clinical Trial
Background/Purpose: Olokizumab (OKZ) is a direct interleukin-6 inhibitor for treatment of rheumatoid arthritis and is being investigated in the open-label Phase 2 trial in adolescents…Abstract Number: 1058 • ACR Convergence 2024
Bridging the Care Gap Between Hospital Discharge and Outpatient Care Transition for Pediatric Rheumatology Patients: An RN-led Quality Improvement Project
Background/Purpose: When pediatric rheumatology patients are discharged from a hospital, the period between hospital discharge & outpatient care transition creates a care gap when there…Abstract Number: 1270 • ACR Convergence 2024
Association of Disease-Modifying Anti-Rheumatic Drug Selection with Hospitalized Infection in Youth with Childhood-Onset Systemic Lupus Erythematosus
Background/Purpose: Youth with childhood-onset systemic lupus erythematosus (cSLE) have increased risk of serious infection. It is unknown how much of this risk is due to…Abstract Number: 1317 • ACR Convergence 2024
Serum (1-3)-β-D-Glucan Levels in Juvenile Idiopathic Arthritis
Background/Purpose: Juvenile idiopathic arthritis (JIA) encompasses the most common chronic rheumatologic manifestations in children. It results from the interplay of genetic, environmental, and infectious factors.…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 52
- Next Page »